Neuroendocrine Tumors – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Neuroendocrine Tumors – Pipeline Review, H2 2016’, provides an overview of the Neuroendocrine Tumors pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Neuroendocrine Tumors, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Neuroendocrine Tumors and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Neuroendocrine Tumors

The report reviews pipeline therapeutics for Neuroendocrine Tumors by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Neuroendocrine Tumors therapeutics and enlists all their major and minor projects

The report assesses Neuroendocrine Tumors therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Neuroendocrine Tumors

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Neuroendocrine Tumors

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Neuroendocrine Tumors pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AbbVie Inc

Advanced Accelerator Applications SA

Aegis Therapeutics LLC

Amgen Inc

Amryt Pharma plc

AVEO Pharmaceuticals Inc

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company

Celgene Corp

Chiasma Inc

Crinetics Pharmaceuticals Inc

Daiichi Sankyo Company Ltd

DexTech Medical AB

Eisai Co Ltd

Eli Lilly and Company

Esperance Pharmaceuticals Inc

Exelixis Inc

Foresee Pharmaceuticals LLC

Hutchison MediPharma Ltd

INVENT Pharmaceuticals Inc

Ipsen SA

Jiangsu Hengrui Medicine Co Ltd

Karyopharm Therapeutics Inc

Lexicon Pharmaceuticals Inc

Mateon Therapeutics Inc

Merck & Co Inc

Midatech Pharma Plc

Millennium Pharmaceuticals Inc

MolMed SpA

Northwest Biotherapeutics Inc

Novartis AG

Peptron Inc

Pfizer Inc

Pharma Mar SA

Progenics Pharmaceuticals Inc

Provectus Biopharmaceuticals Inc

Strongbridge Biopharma plc

Taiwan Liposome Company Ltd

Threshold Pharmaceuticals Inc

Vascular Biogenics Ltd

Xencor Inc

Table of Contents

Table of Contents

Table of Contents 2

Introduction 5

Neuroendocrine Tumors Overview 6

Therapeutics Development 7

Neuroendocrine Tumors - Therapeutics under Development by Companies 9

Neuroendocrine Tumors - Therapeutics under Investigation by Universities/Institutes 12

Neuroendocrine Tumors - Pipeline Products Glance 13

Neuroendocrine Tumors - Products under Development by Companies 16

Neuroendocrine Tumors - Products under Investigation by Universities/Institutes 20

Neuroendocrine Tumors - Companies Involved in Therapeutics Development 21

Neuroendocrine Tumors - Therapeutics Assessment 62

Drug Profiles 75

Neuroendocrine Tumors - Dormant Projects 335

Neuroendocrine Tumors - Discontinued Products 337

Neuroendocrine Tumors - Product Development Milestones 338

Appendix 349

List of Tables

List of Tables

Number of Products under Development for Neuroendocrine Tumors, H2 2016 14

Number of Products under Development for Neuroendocrine Tumors – Comparative Analysis, H2 2016 15

Number of Products under Development by Companies, H2 2016 16

Number of Products under Development by Companies, H2 2016 (Contd..1) 17

Number of Products under Development by Companies, H2 2016 (Contd..2) 18

Number of Products under Investigation by Universities/Institutes, H2 2016 19

Comparative Analysis by Late Stage Development, H2 2016 20

Comparative Analysis by Clinical Stage Development, H2 2016 21

Comparative Analysis by Early Stage Development, H2 2016 22

Products under Development by Companies, H2 2016 23

Products under Development by Companies, H2 2016 (Contd..1) 24

Products under Development by Companies, H2 2016 (Contd..2) 25

Products under Development by Companies, H2 2016 (Contd..3) 26

Products under Investigation by Universities/Institutes, H2 2016 27

Neuroendocrine Tumors – Pipeline by AbbVie Inc, H2 2016 28

Neuroendocrine Tumors – Pipeline by Advanced Accelerator Applications SA, H2 2016 29

Neuroendocrine Tumors – Pipeline by Aegis Therapeutics LLC, H2 2016 30

Neuroendocrine Tumors – Pipeline by Amgen Inc, H2 2016 31

Neuroendocrine Tumors – Pipeline by Amryt Pharma plc, H2 2016 32

Neuroendocrine Tumors – Pipeline by AVEO Pharmaceuticals Inc, H2 2016 33

Neuroendocrine Tumors – Pipeline by Boehringer Ingelheim GmbH, H2 2016 34

Neuroendocrine Tumors – Pipeline by Bristol-Myers Squibb Company, H2 2016 35

Neuroendocrine Tumors – Pipeline by Celgene Corp, H2 2016 36

Neuroendocrine Tumors – Pipeline by Chiasma Inc, H2 2016 37

Neuroendocrine Tumors – Pipeline by Crinetics Pharmaceuticals Inc, H2 2016 38

Neuroendocrine Tumors – Pipeline by Daiichi Sankyo Company Ltd, H2 2016 39

Neuroendocrine Tumors – Pipeline by DexTech Medical AB, H2 2016 40

Neuroendocrine Tumors – Pipeline by Eisai Co Ltd, H2 2016 41

Neuroendocrine Tumors – Pipeline by Eli Lilly and Company, H2 2016 42

Neuroendocrine Tumors – Pipeline by Esperance Pharmaceuticals Inc, H2 2016 43

Neuroendocrine Tumors – Pipeline by Exelixis Inc, H2 2016 44

Neuroendocrine Tumors – Pipeline by Foresee Pharmaceuticals LLC, H2 2016 45

Neuroendocrine Tumors – Pipeline by Hutchison MediPharma Ltd, H2 2016 46

Neuroendocrine Tumors – Pipeline by INVENT Pharmaceuticals Inc, H2 2016 47

Neuroendocrine Tumors – Pipeline by Ipsen SA, H2 2016 48

Neuroendocrine Tumors – Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2016 49

Neuroendocrine Tumors – Pipeline by Karyopharm Therapeutics Inc, H2 2016 50

Neuroendocrine Tumors – Pipeline by Lexicon Pharmaceuticals Inc, H2 2016 51

Neuroendocrine Tumors – Pipeline by Mateon Therapeutics Inc, H2 2016 52

Neuroendocrine Tumors – Pipeline by Merck & Co Inc, H2 2016 53

Neuroendocrine Tumors – Pipeline by Midatech Pharma Plc, H2 2016 54

Neuroendocrine Tumors – Pipeline by Millennium Pharmaceuticals Inc, H2 2016 55

Neuroendocrine Tumors – Pipeline by MolMed SpA, H2 2016 56

Neuroendocrine Tumors – Pipeline by Northwest Biotherapeutics Inc, H2 2016 57

Neuroendocrine Tumors – Pipeline by Novartis AG, H2 2016 58

Neuroendocrine Tumors – Pipeline by Peptron Inc, H2 2016 59

Neuroendocrine Tumors – Pipeline by Pfizer Inc, H2 2016 60

Neuroendocrine Tumors – Pipeline by Pharma Mar SA, H2 2016 61

Neuroendocrine Tumors – Pipeline by Progenics Pharmaceuticals Inc, H2 2016 62

Neuroendocrine Tumors – Pipeline by Provectus Biopharmaceuticals Inc, H2 2016 63

Neuroendocrine Tumors – Pipeline by Strongbridge Biopharma plc, H2 2016 64

Neuroendocrine Tumors – Pipeline by Taiwan Liposome Company Ltd, H2 2016 65

Neuroendocrine Tumors – Pipeline by Threshold Pharmaceuticals Inc, H2 2016 66

Neuroendocrine Tumors – Pipeline by Vascular Biogenics Ltd, H2 2016 67

Neuroendocrine Tumors – Pipeline by Xencor Inc, H2 2016 68

Assessment by Monotherapy Products, H2 2016 69

Number of Products by Stage and Target, H2 2016 71

Number of Products by Stage and Mechanism of Action, H2 2016 75

Number of Products by Stage and Route of Administration, H2 2016 79

Number of Products by Stage and Molecule Type, H2 2016 81

Neuroendocrine Tumors – Dormant Projects, H2 2016 342

Neuroendocrine Tumors – Dormant Projects (Contd..1), H2 2016 343

Neuroendocrine Tumors – Discontinued Products, H2 2016 344

List of Figures

List of Figures

Number of Products under Development for Neuroendocrine Tumors, H2 2016 14

Number of Products under Development for Neuroendocrine Tumors – Comparative Analysis, H2 2016 15

Number of Products under Development by Companies, H2 2016 16

Number of Products under Investigation by Universities/Institutes, H2 2016 19

Comparative Analysis by Late Stage Development, H2 2016 20

Comparative Analysis by Clinical Stage Development, H2 2016 21

Comparative Analysis by Early Stage Products, H2 2016 22

Assessment by Monotherapy Products, H2 2016 69

Number of Products by Top 10 Targets, H2 2016 70

Number of Products by Stage and Top 10 Targets, H2 2016 70

Number of Products by Top 10 Mechanism of Actions, H2 2016 74

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 74

Number of Products by Top 10 Routes of Administration, H2 2016 78

Number of Products by Stage and Top 10 Routes of Administration, H2 2016 78

Number of Products by Molecule Types, H2 2016 80

Number of Products by Stage and Molecule Types, H2 2016 80

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports